Recently, an observation team consisting of Dr. Kelly Catlin, the Process Chemistry Procurement Director of the Clinton Foundation, Ms. Melissa Leavitt, the Product Development and Legal Technical Advisor, and Mr. Xie Hong, the China Project Director, conducted a three-day on-site observation of Dahua Pharmaceutical Company.

The visit of the Clinton Foundation is the first time that the organization's technical team has represented Dahua Pharmaceutical Company's production capacity and preparation for large-scale procurement, ensuring that Dahua Pharmaceutical Company can smoothly complete the production of large purchase orders in the future.

At the meeting, the General Manager of Dahua Pharmaceutical Company warmly welcomed Dr. Kelly and Ms. Melissa who came from afar, and a dedicated person introduced the company's organizational structure, key personnel, major facilities, product regulatory registration, and WHO-PQ progress to the observation group. Both parties discussed the capacity expansion plan of Dahua Pharmaceutical Company, as well as the time required for personnel recruitment and training.

The observation team conducted a detailed investigation of Dahua Company's production area, laboratory area, and public facility area, including air conditioning system, water purification system, and backup power generation system, from the material receiving process to the issuance of finished products. Dr. Kelly expressed satisfaction with the results of this on-site dynamic inspection and believed that Dahua Pharmaceutical Company's existing production line can meet the production capacity required for future large orders. He hopes that the company can continue to maintain its existing product quality and production processes, and make sufficient preparations for production orders after obtaining PQ.